Gilead told to pay Merck $2.5B in Hep C royalties

Shares of Gilead sink after-hours following a court order to pay Merck $2.5 billion in Hepatitis C royalties. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.